Ocd

OCD

Long-term efficacy (more than 24 weeks) has not been demonstrated in OCD.
http://www.emea.europa.eu/

Effekten ved behandling udover 24 uger er ikke på vist for OCD.
http://www.emea.europa.eu/

Hostility events were more clearly seen in the OCD studies than in the depression studies.

Hændelser med fjendtlig adfærd blev observeret tydeligere i OCD-undersøgelserne end i depressionsundersøgelserne.

Patients with OCD should be treated for a sufficient period to ensure that they are free from symptoms.
http://www.emea.europa.eu/

Patienter med OCD skal behandles i en tilstrækkelig lang periode til at sikre, at de er symptomfri.
http://www.emea.europa.eu/

efficacy of paroxetine in treating OCD was examined in three 24 week maintenance studies with relapse prevention design.
http://www.emea.europa.eu/

Langtidseffekten af paroxetin i behandlingen af OCD blev undersøgt i tre 24 ugers ” maintenance study ”, med et tilbagefaldsforebyggende design.
http://www.emea.europa.eu/

The recommended daily dose of paroxetine is 40mg/day for OCD and panic disorder and 20mg/day for the other indications.

Den anbefalede daglige dosis af paroxetin er 40 mg/dag for OCD og panikangst og 20 mg/dag for de andre indikationer.

50/72 efficacy of paroxetine in treating OCD was examined in three 24 week maintenance studies with relapse prevention design.

51/73 undersøgelser.Langtidseffekten af paroxetin i behandlingen af OCD blev undersøgt i tre 24 ugers " maintenance study ", med et tilbagefaldsforebyggende design.

Obsessive Compulsive Disorder The efficacy of paroxetine in treating OCD in adults was investigated in short-term and long-term studies.

Obsessiv-kompulsiv tilstand (OCD) Virkningen af paroxetin til behandling af OCD hos voksne er blevet undersøgt i kort -og langvarige undersøgelser.

Obsessive Compulsive Disorder The efficacy of paroxetine in treating OCD in adults was investigated in short-term and long-term studies.
http://www.emea.europa.eu/

Obsessiv- kompulsiv tilstand (OCD) Virkningen af paroxetin til behandling af OCD hos voksne er blevet undersøgt i kort - og langvarige undersøgelser.
http://www.emea.europa.eu/

They are OCD aid eligibility with regard to Structural Funds, a revised EDF, or a fund specially intended for OCDs in the Union budget.
http://www.europarl.europa.eu/

De er støttekapaciteten til de oversøiske lande og territorier i forhold til strukturfondene, en reformeret EUF, eller en fond specielt beregnet for de oversøiske lande og territorier i Unionens budget.
http://www.europarl.europa.eu/

Suicidal related behaviours associated with paroxetine in the clinical trials were more clearly seen in the depression studies than in studies of OCD or SAD.
http://www.emea.europa.eu/

I kliniske forsøg blev selvmordsrelateret adfærd, associeret med paroxetin, observeret tydeligere i depressionsundersøgelser end i OCD - eller SAD- undersøgelser.
http://www.emea.europa.eu/

Suicidal related behaviours associated with paroxetine in the clinical trials were more clearly seen in the depression studies than in studies of OCD or SAD.

I kliniske forsøg blev selvmordsrelateret adfærd, associeret med paroxetin, observeret tydeligere i depressionsundersøgelser end i OCD -eller SAD-undersøgelser.

Only some of these medicines are authorised for the treatment of obsessive-compulsive disorder (OCD) in children and adolescents and atomoxetine is authorised for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents.

Kun nogle af disse lægemidler er godkendt til behandling af obsessiv-kompulsiv sygdom (obsessive-compulsive disorder -OCD) hos børn og unge, og atomoxetin er godkendt til behandling af opmærksomheds -og hyperaktivitetsforstyrrelse (Attention Deficit Hyperactivity Disorder ­ ADHD) hos børn og unge.

While there are no systematic studies to answer the question of how long to continue fluoxetine treatment, OCD is a chronic condition and it is reasonable to consider continuation beyond 10 weeks in responding patients.
http://www.emea.europa.eu/

undersøgelser, der viser hvor lang tid man bør fortsætte fluoxetin- behandlingen; men idet OCD er en kronisk tilstand, vil det være rimeligt at overveje behandling udover 10 uger hos responderende patienter.
http://www.emea.europa.eu/

Only some of these medicines are authorised for the treatment of obsessive-compulsive disorder (OCD) in children and adolescents and atomoxetine is authorised for the treatment of attention deficit/ hyperactivity disorder (ADHD) in children and adolescents.
http://www.emea.europa.eu/

Kun nogle af disse lægemidler er godkendt til behandling af obsessiv- kompulsiv sygdom (obsessive- compulsive disorder - OCD) hos børn og unge, og atomoxetin er godkendt til behandling af opmærksomheds - og hyperaktivitetsforstyrrelse (Attention Deficit Hyperactivity Disorder – ADHD) hos børn og unge.
http://www.emea.europa.eu/

The indications for which paroxetine is currently approved in EU includemajor depressive disorder (MDD) , panic disorder, obsessive compulsive disorder (OCD) , social phobia/social anxiety disorder (SAD) , generalised anxiety disorder (GAD) and post-traumatic stress disorder (PTSD) .

De indikationer, til hvilke paroxetin på nuværende tidspunkt er godkendt i EU, omfatter moderat til svær depression (major depressive disorder -MDD) , panikangst, obsessiv-kompulsiv tilstand (obsessive compulsive disorder -OCD) , socialfobi (social phobia/social anxiety disorder -SAD) , generaliseret angstsyndrom (generalised anxiety disorder -GAD) og posttraumatisk stress-syndrom (post-traumatic stress disorder -PTSD) .

In May 2003 UK reviewed data from clinical trials with paroxetine in the treatment of paediatric OCD, SAD and MDD and concluded that these data provided evidence of an association between the use of paroxetine and an increased risk of emotional lability including self-harm, hostility and suicidal behaviour in children and adolescents.

I maj 2003 gennemgik Det Forenede Kongerige data fra kliniske forsøg med paroxetin i behandlingen af pædiatrisk OCD, SAD og MDD og konkluderede, at disse data viser evidens af en sammenhæng mellem brugen af paroxetin og en øget risiko for emotionel labilitet, inklusive selvdestruktiv adfærd, fjendtlig adfærd og selvmordsadfærd hos børn og unge.

On the basis of the available data the CHMP concluded that if after some weeks on the recommended dose insufficient response is seen some patients may benefit from having their dose gradually increased (in 10 mg steps) up to a maximum of 50mg/day for MDD, SAD, GAD and PTSD and up to a maximum of 60mg/day for OCD and panic disorder.

På basis af de tilgængelige data konkluderede CHMP, at nogle patienter, hvis der efter nogle uger på den anbefalede dosis observeres utilstrækkelig respons, kan have gavn af at få deres dosis gradvis forøget (i trin på 10 mg) op til maksimalt 50 mg/dag for MDD, SAD, GAD og PTSD og op til maksimalt 60 mg/dag for OCD og panikangst.

The Council will be debating the details of an improved financial instrument for OCDs once it has its possession, in the near future, the awaited Commission proposal on a definition of the new association system for OCDs to be applied on 1 March 2000.

Rådet behandler forbedringen af det finansielle instrument for de oversøiske lande og territorier detaljeret, så snart det har modtaget et snarligt ventet kommissionsforslag, som behandler bestemmelserne for associeringsaftalen for de oversøiske lande og territorier, som skal træde i kraft den 1. marts 2000.

Adults and the elderly:The recommended dose is 20mg daily.Although there may be an increased potential for undesirable effects at higher doses in some patients, if after two weeks there is insufficient response to 20mg, the dose may be increased gradually up to a maximum of 60mg.If no improvement is observed within 10 weeks, treatment with fluoxetine should be reconsidered.If a good therapeutic response has been obtained, treatment can be continued at a dosage adjusted on an individual basis.While there are no systematic studies to answer the question of how long to continue fluoxetine treatment, OCD is a chronic condition and it is reasonable to consider continuation beyond 10 weeks in responding patients.Dosage adjustments should be made carefully on an individual patient basis, to maintain the patient at the lowest effective dose.The need for treatment should be reassessed periodically.Some clinicians advocate concomitant behavioural psychotherapy for patients who have done well on pharmacotherapy.Long-term efficacy (more than 24 weeks) has not been demonstrated in OCD.

Justering af dosis bør foretages på en individuel basis, således at patienten kan holdes på den laveste effektive dosis.Behovet for behandling bør periodisk revurderes.Nogle læger er fortalere for samtidig adfærdsterapi til patienter, der har responderet på medicinsk behandling.Effekten ved behandling udover 24 uger er ikke på vist for OCD.